News & Updates

The adjuvant chemotherapy regimen epirubicin plus paclitaxel (EP) appears to be as good as the regimen that consists of epirubicin and cyclophosphamide followed by paclitaxel (EC-P) in the treatment of Asian women with operable ERBB2-negative breast cancer, according to the results of an open-label phase III trial.

In a recent study, seliciclib therapy demonstrates its potential in reversing hypercortisolism by directly targeting pituitary corticotrophs in Cushing disease (CD). However, the agent is associated with liver toxicity, which is resolved by withdrawing treatment.

Treatment with tyrosine kinase inhibitors (TKIs), such as sunitinib, provides survival benefits to patients with metastatic pheochromocytomas/paragangliomas (PPGLs), suggests a recent study.

In individuals with stable coronary artery disease (CAD), intensifying their lipid-lowering regimen with evolocumab, a PCSK9* inhibitor, led to improvements in coronary plaque characteristics on intravascular imaging, findings from the YELLOW III trial have shown.

In a post hoc analysis of two prospective studies, netupitant/palonosetron (NEPA) combined with dexamethasone has demonstrated similar efficacy vs a quadruplet regimen of olanzapine, aprepitant, ondansetron, and dexamethasone in preventing chemotherapy-induced nausea and vomiting (CINV) in Chinese women with early breast cancer (BC) receiving doxorubicin/cyclophosphamide (AC) in Hong Kong.